Dna Script Closes $200 Million Series C Financing With Completion Of Second Tranche

Jan 04, 2022•over 3 years ago

Amount Raised

$200 Million

Round Type

series c

San Francisco

Description

DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.

Company Information

Company

Dna Script

Location

San Francisco, California, United States

About

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech